BOSTON HEART DIAGNOSTICS

Oxidized Phospholipids-ApoB

Boston Heart Diagnostics is proud to be the first reference laboratory to offer **Oxidized Phospholipids (OxPL-apoB).**

Oxidized phospholipids are found on all apoB-containing lipoproteins, including LDL, VLDL, and especially on Lp(a) [8,9].

1 in 4
Boston Heart patients
have an increased risk OxPL-apoB level

OXIDIZED PHOSPHOLIPIDS ARE HIGHLY PRO-INFLAMMATORY AND CONTRIBUTE TO MANY DISEASES OF AGING

When taken up by the artery wall, oxidized lipoproteins accelerate atherosclerosis, and increase the risk of myocardial infarctions, strokes, and calcific aortic valve stenosis [1-9].

Clinicians can use OxPL-apoB levels to reclassify patients into higher or lower risk categories allowing better personalized care.



Lp(a): The primary carrier of oxidized phospholipids

ABOUT OxPL-apoB

1. **OxPL-apoB measurement is superior to oxidized LDL (ox-LDL)** in CVD risk prediction and its clinical utility has been demonstrated in 42 clinical studies involving more than 80,000 patients [1-7]

2. **Advantages of OxPL-apoB over ox-LDL** are that OxPL-apoB measures oxidized phospholipids on ALL apo B-containing particles, and does not correlate with serum apoB levels.[8,9]

3. **Two- to three-fold increased CVD risk** is seen in individuals with an OxPL-apoB in the increased risk category as compared to those with values below this threshold [1-7].

4. **If OxPL-apoB levels are high**, consider maximal preventative therapies, including optimal lipid management, blood pressure and diabetes control, cessation of smoking and weight loss if appropriate.

bostonheart diagnostics®

OxPL-apoB CUMULATIVE HAZARD CURVES FOR CVD AND STROKE

Cumulative hazard curves for CVD incidence and stroke incidence by OxPL tertile groups. There were 138 cases of incident CVD and 60 cases of incident stroke in 765 patients followed for 15 years (1995-2010). From Tsimikas et al. JACC 2012.



Tsimikas et al., JACC 2012



ORDERING, REPORTING, AND SAMPLE INFORMATION

Ordering Information

- The order code is: 635

Report and Reference Ranges

- OxPL-apoB will be reported in the Inflammation and Oxidation section of the lab report
- The reference ranges below will be reported.

Optimal	Borderline	Increased Risk
< 2.0	2.0 -3.0	> 3.0 nmol/L

Specimen Requirements

- Serum collected in a serum separator tube (SST/Tiger top)

References

1. Tsimikas S et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol. 2010; 56:946-955.
2. Tsimikas S at al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012; 60:2218-2229.
3. Byun YS et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: The TNT Trial. J Am Coll Cardiol. 2015; 65:1286-1295.
4. Kamstrup PR et al. Oxidized phospholipids and risk of calcific aortic valve disease The Copenhagen General Population Study. Arterioscler Thromb Vasc Biol. 2017; 37:1570-1578.
5. Tsimikas S at al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012; 60:2218-2229.
6. Byun YS et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: The TNT Trial. J Am Coll Cardiol. 2015; 65:1286-1295.
7. Kamstrup PR et al. Oxidized phospholipids and risk of calcific aortic valve disease The Copenhagen General Population Study. Arterioscler Thromb Vasc Biol. 2017; 37:1570-1578.
8. van der Valk FM et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016; 134:611-624.
9. Bergmark C et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008; 49:2230-2239.
10. Ikezaki H et al. Direct versus calculated LDL cholesterol and C-reactive protein in cardiovascular disease risk assessment in the Framingham Offspring Study. Clin Chem. 2019; 65:1102-1114.
11. Lamon-Fava S et al. Lipoprotein(a) levels, isoforms, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res. 2011; 52:1181-7.
12. Ky B et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol. 2008; 51:1653-1662.
13. Tsimikas S et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.Circulation. 2004; 110:1406-1412.
14. O'Donoghue ML et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019; 139:1483-1492.
15. Tsimikas S, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244-255..
16. Chasman DI et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009; 203:371–376.

877.425.1252 bostonheartdiagnostics.com

03290922

bostonheart diagnostics®